ArticleBMJ public health2026
8 years of strengthening AMR response capacity in the WHO African region (2017-2024): progress in antimicrobial consumption monitoring, surveillance and laboratory capacity.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combating Bacterial Infection with Metabolism-Regulating Nanomaterials.International journal of nanomedicine · 2026Review
- Strengthening One Health AMR Surveillance in Africa: From Cross-Sectoral Data to Policy Action.Infection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antimicrobial resistance (AMR) is a major global health threat, and African countries are disproportionately affected due to limited diagnostic capacity, weak surveillance and inadequate monitoring of antimicrobial consumption (AMC). This study analysed regional trends using the Tracking Antimicrobial Resistance Country Self-Assessment Survey (TrACSS), a standardised tool for monitoring national progress in AMR response. Methods: We conducted an analysis of the TrACSS database covering 47 African countries (2017-2024). Indicators included national AMC monitoring systems, national AMR surveillance systems and laboratory capacity focusing on public and private bacteriology coverage and antimicrobial susceptibility testing (AST) for WHO-priority bacteria and critical fungi. Descriptive and trend analyses were performed, and the association between AMC and AMR system maturity was examined using logistic regression and correlation tests. Results: Between 2017 and 2024, the proportion of countries with advanced AMC monitoring more than doubled (13%-30%), while advanced AMR surveillance quadrupled (13%-57%). From 2022 to 2024, public-sector bacteriology coverage rose from 80%-94% and private sector coverage from 60%-75%. Nearly all countries (95.7% in 2024) reported at least one reference laboratory performing AST for priority bacteria, though pathogen-specific reporting remained limited, with the lowest capacity for Conclusion: The WHO African Region has made measurable progress in AMR response over the past 8 years, though gains remain uneven. Strengthening mycology services, expanding bacteriology coverage and integrating AMC and AMR data systems are critical next steps towards achieving resilient, evidence-driven surveillance networks that can better guide stewardship and investment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.